|
1
|
Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Khan AS and Dageforde LA: Cholangiocarcinoma. Surg Clin North Am. 99:315–335. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Khan SA, Tavolari S and Brandi G: Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 39 (Suppl 1):S19–S31. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Razumilava N and Gores GJ: Cholangiocarcinoma. Lancet. 383:2168–2179. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Patel T: Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 8:189–200. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G and Labianca R: Cholangiocarcinoma. Crit Rev Oncol Hematol. 116:11–31. 2017.
|
|
7
|
Blechacz B: Cholangiocarcinoma: Current knowledge and new developments. Gut Liver. 11:13–26. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ebata T, Mizuno T, Yokoyama Y, Igami T, Sugawara G and Nagino M: Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg. 105:829–838. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20:515–524. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wei R, Ye X, Zhao Y, Jia N, Liu T, Lian W, Wei H, Zhang G and Song L: MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A. Oncol Lett. 17:3211–3218. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yao R, Zheng H, Wu L and Cai P: miRNA-641 inhibits the proliferation, migration, and invasion and induces apoptosis of cervical cancer cells by directly targeting ZEB1. Onco Targets Ther. 11:8965–8976. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hrdlicka HC, Lee SK and Delany AM: MicroRNAs are critical regulators of osteoclast differentiation. Curr Mol Biol Rep. 5:65–74. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Iwai N, Yasui K, Tomie A, Gen Y, Terasaki K, Kitaichi T, Soda T, Yamada N, Dohi O, Seko Y, et al: Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. Int J Oncol. 53:237–245. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Iseki Y, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Hirakawa K and Ohira M: MicroRNA-96 promotes tumor invasion in colorectal cancer via RECK. Anticancer Res. 38:2031–2035. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Xie W, Sun F, Chen L and Cao X: miR-96 promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett. 15:3464–3471. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM and Bloomston M: A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol. 21:133–138. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shi W, Hasimu G, Wang Y, Li N, Chen M and Zhang H: MTSS1 is an independent prognostic biomarker for survival in intrahepatic cholangiocarcinoma patients. Am J Transl Res. 7:1974–1983. 2015.PubMed/NCBI
|
|
19
|
Wang F, Liu Y and Zhang H: Loss of MTSS1 expression is an independent prognostic factor for Hilar cholangiocarcinoma. Pathol Oncol Res. 19:815–820. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kirstein MM and Vogel A: Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 32:395–400. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Puik JR, Meijer LL, Le Large TY, Prado MM, Frampton AE, Kazemier G and Giovannetti E: miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics. 18:1343–1358. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut. 61:1657–1669. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang ZQ, Wu CA and Cheng YX: Prognostic value of microRNA-133a expression and its clinicopathologic significance in Non-small cell lung cancer: A comprehensive study based on Meta-analysis and the TCGA database. Oncol Res Treat. 41:762–768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang JR, Liu B, Zhou L and Huang YX: MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer. Cancer Biomark. 24:159–172. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Karimi N, Ali Hosseinpour Feizi M, Safaralizadeh R, Hashemzadeh S, Baradaran B, Shokouhi B and Teimourian S: Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer. J Chin Med Assoc. 82:215–220. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sekar D, Mani P, Biruntha M, Sivagurunathan P and Karthigeyan M: Dissecting the functional role of microRNA 21 in osteosarcoma. Cancer Gene Ther. 26:179–182. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Papadaki C, Stoupis G, Tsalikis L, Monastirioti A, Papadaki M, Maliotis N, Stratigos M, Mastrostamatis G, Mavroudis D and Agelaki S: Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. Oncotarget. 10:966–981. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Qin C, Huang RY and Wang ZX: Potential role of miR-100 in cancer diagnosis, prognosis, and therapy. Tumour Biol. 36:1403–1409. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sun D, Zhong J, Wei W, Chen X, Liu J and Hu Z: Identification of microRNA expression in sentinel lymph nodes from patients with breast cancer via RNA sequencing for diagnostic accuracy. J Gene Med. 21(e3075)2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fei X, Zhang J, Zhao Y, Sun M, Zhao H and Li S: MiR-96 promotes invasion and metastasis by targeting GPC3 in non-small cell lung cancer cells. Oncol Lett. 15:9081–9086. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ma X, Shi W, Peng L, Qin X and Hui Y: MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9. Saudi J Biol Sci. 25:863–867. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li Z and Wang Y: miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma. Biochem Cell Biol. 96:365–371. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yuan J, Dong R, Liu F, Zhan L, Liu Y, Wei J and Wang N: The miR-183/182/96 cluster functions as a potential carcinogenic factor and prognostic factor in kidney renal clear cell carcinoma. Exp Ther Med. 17:2457–2464. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sha HH, Wang DD, Chen D, Liu SW, Wang Z, Yan DL, Dong SC and Feng JF: MiR-138: A promising therapeutic target for cancer. Tumour Biol. 39(1010428317697575)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhou MH, Zhou HW, Liu M and Sun JZ: The role of miR-92b in cholangiocarcinoma patients. Int J Biol Markers. 33:293–300. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang N, Zhou J, Li Q, Han F and Yu Z: miR-96 exerts carcinogenic effect by activating AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma. Cancer Cell Int. 19(38)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu K, Jiao XD, Hao JL, Qin BD, Wu Y, Chen W, Liu J, He X and Zang YS: MTSS1 inhibits metastatic potential and induces G2/M phase cell cycle arrest in gastric cancer. Onco Targets Ther. 12:5143–5152. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Du P, Wang S, Tang X, An C, Yang Y and Jiang WG: Reduced expression of metastasis Suppressor-1 (MTSS1) accelerates progression of human bladder uroepithelium cell carcinoma. Anticancer Res. 37:4499–4505. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Taylor MD, Bollt O, Iyer SC and Robertson GP: Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma. Clin Exp Metastasis. 35:15–23. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang H, Zhao Y, Cao L, Zhang J, Wang Y and Xu M: Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling. J Cell Biochem. 120:3447–3454. 2019.PubMed/NCBI View Article : Google Scholar
|
